<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2596">
  <stage>Registered</stage>
  <submitdate>1/12/2009</submitdate>
  <approvaldate>1/12/2009</approvaldate>
  <nctid>NCT01025713</nctid>
  <trial_identification>
    <studytitle>A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)</studytitle>
    <scientifictitle>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-221-0106</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <healthcondition>Mucociliary Clearance</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GS-9411
Treatment: drugs - Placebo

Experimental: 1 - GS-9411 2.4 mg

Experimental: 2 - GS-9411 4.8 mg

Placebo Comparator: Placebo - Placebo


Treatment: drugs: GS-9411
Inhaled GS-9411

Treatment: drugs: Placebo
Inhaled Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the safety and tolerability of escalating doses of inhaled GS-9411 in subjects with CF.</outcome>
      <timepoint>5 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the pharmacokinetics (PK) of GS-9411 and its metabolites, in plasma, urine, and sputum after single inhaled doses.</outcome>
      <timepoint>5 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and females aged 18 to 65 years

          -  Patients with diagnosis of CF as confirmed by at least one of the following:

          -  Documented sweat chloride = 60 mEq/L by quantitative pilocarpine iontophoresis test OR

          -  Documented sweat sodium test = 60 mmol/L OR

          -  Abnormal nasal potential difference test OR

          -  At least one well-characterized disease-causing genetic mutation in the CF
             transmembrane conductance regulatory (CFTR) gene AND

          -  Accompanying symptoms characteristic of CF

          -  Normal (or abnormal but not clinically significant) electrocardiogram (ECG)

          -  Normal intraocular pressure (IOP) between 10 and 21 mm Hg at Screening.

          -  Normal (or abnormal but not clinically significant) blood pressure (BP) and heart rate
             (HR) in the absence of any medications for hypertension; these will be measured after
             the subject has rested supine for 3 minutes; normal BP is taken to be 90 to 140 mm Hg
             systolic and 50 to 89 mm Hg diastolic; normal HR is taken to be 40 to 100 beats per
             minute (bpm)

          -  Able to communicate well with the investigator and to comply with the requirements of
             the entire study

          -  Provision of written informed consent to participate as shown by a signature on the
             volunteer consent form

          -  Nonsmokers for at least 180 days (6 months) prior to Screening

          -  Must be willing to abstain from alcohol and strenuous exercise during the 48 hours
             prior to Screening, 72 hours prior to initial dosing, and during the study

          -  Forced expiratory volume in 1 second (FEV1) = 50% predicted normal for age, gender,
             and height at Screening as per Knudson et al

          -  Stable regimen of oral CF medications, dornase alfa, and physiotherapies for the
             period 28 days prior to Screening; those subjects taking continuous (non-cycling)
             inhaled antibiotics for prophylaxis must be on a stable regimen of these drugs for at
             least 90 days prior to Screening

          -  Subjects must be in the off-phase of any cyclical inhaled antibiotic treatment regimen

          -  Must test negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human
             immunodeficiency virus (HIV) at Screening

          -  Male subjects who are sexually active must be willing to use effective barrier
             contraception (e.g., condom) during heterosexual intercourse from Day -1 through
             completion of the study and continuing for at least 90 days from date of last dose of
             study drug

          -  Male subjects must refrain from sperm donation from Day -1 through completion of the
             study and continuing for at least 90 days from the date of last dose of study drug

          -  Nonlactating females. Females on hormone replacement therapy (estrogen/progesterone)
             or contraceptive therapy must be stabilized on a product and dose for at least 90 days
             prior to Screening

          -  Females must have a negative serum gonadotropin pregnancy test at Screening and Day -1

          -  Nonpregnant females of childbearing potential must agree to use highly effective (&lt;1%
             failure rate) contraception during heterosexual intercourse from Screening, throughout
             the study, and for at least 30 days following the last dose of study drug

          -  Glomerular filtration rate (GFR) of &lt; 60 mL/min/1.73m2 at Screening (GFR to be
             calculated using the Cockcroft-Gault equation), and alanine aminotransferase (ALT) and
             aspartate aminotransferase (AST) less than or equal to 3Ã— upper limits of normal (ULN)

          -  Chest radiograph at Screening without significant acute findings (e.g., infiltrates
             [lobar or diffuse interstitial], pleural effusion, pneumothorax); or chest radiograph,
             CT, or MRI obtained within the 90 days prior to Screening without acute findings or
             significant intercurrent illness; chronic, stable findings (e.g., chronic scarring or
             atelectasis) are allowed. A chest radiograph obtained and interpreted between
             Screening and Day 1 is also acceptable for determining eligibility.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Administration of any investigational drug or device in the 28 days prior to Screening

          -  A need for any new medication during the period 28 days before first dosing with study
             drug, except those deemed by the principal investigator/clinical investigator not to
             interfere with the outcome of the study

          -  Subjects who routinely use inhaled hypertonic saline must discontinue use for at least
             14 days prior to clinic admission and for the duration of the study

          -  Use of trimethoprim or high dose ibuprofen (&gt; 800 mg/day) during the 28 days prior to
             first dosing

          -  Serious adverse reaction or hypersensitivity to any drug

          -  Existence of any surgical or medical condition which, in the judgment of the clinical
             investigator, might interfere with the absorption, distribution, metabolism, or
             excretion of the drug

          -  Lactating females

          -  History of airway intolerance to hypertonic saline

          -  History of lung transplantation

          -  History of a positive test for Burkholderia cepacia

          -  History of cirrhosis or ascites

          -  History of clinically significant adrenal disease

          -  History of congestive heart failure diagnosed clinically or with documented left
             ventricular ejection fraction (LVEF) = 40%

          -  History of glaucoma

          -  Consumption of drugs and/or herbal preparations capable of inducing hepatic enzyme
             metabolism (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or
             St. John's Wort) within 28 days (or 5 half-lives of inducing agent, whichever is
             longer) of Screening

          -  Subjects requiring any of the following drugs in the 28 days prior to Screening:
             diuretics (e.g., spironolactone, amiloride, thiazide), ACE inhibitors, angiotensin
             receptor blockers, oral corticosteroids, or medicines for hypertension

          -  Donation or loss of greater than 400 mL of blood in the period 90 days (3 months)
             prior to Screening

          -  Major surgery within 180 days (6 months) of Screening

          -  Hemoglobin levels &lt; 120 g/L in females or &lt; 130 g/L in males taken at Screening and at
             Day -1

          -  Serum potassium &gt; 5 mEq/L taken at Screening and at Day -1

          -  Poor venous access</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/12/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2010</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network, Ltd. - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and tolerability of GS-9411 in patients
      with Cystic Fibrosis. GS-9411 is a sodium channel inhibitor, that may restore airway
      hydration and mucociliary clearance in the lung.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01025713</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Wilson, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>